These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9508337)

  • 1. The neuropeptide/mast cell secretagogue substance P is expressed in cutaneous melanocytic lesions.
    Khare VK; Albino AP; Reed JA
    J Cutan Pathol; 1998 Jan; 25(1):2-10. PubMed ID: 9508337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the mast cell growth factor interleukin-3 in melanocytic lesions correlates with an increased number of mast cells in the perilesional stroma: implications for melanoma progression.
    Reed JA; McNutt NS; Bogdany JK; Albino AP
    J Cutan Pathol; 1996 Dec; 23(6):495-505. PubMed ID: 9001979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions.
    Yu L; Harms PW; Pouryazdanparast P; Kim DS; Ma L; Fullen DR
    Mod Pathol; 2010 Sep; 23(9):1209-14. PubMed ID: 20495543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions.
    Miracco C; Cevenini G; Franchi A; Luzi P; Cosci E; Mourmouras V; Monciatti I; Mannucci S; Biagioli M; Toscano M; Moretti D; Lio R; Massi D
    Hum Pathol; 2010 Apr; 41(4):503-12. PubMed ID: 20004946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin D1 and D3 expression in melanocytic skin lesions.
    Alekseenko A; Wojas-Pelc A; Lis GJ; Furgał-Borzych A; Surówka G; Litwin JA
    Arch Dermatol Res; 2010 Sep; 302(7):545-50. PubMed ID: 20496072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
    Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
    Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical melanocytic nevi of the genital type with a discussion of reciprocal parenchymal-stromal interactions in the biology of neoplasia.
    Clark WH; Hood AF; Tucker MA; Jampel RM
    Hum Pathol; 1998 Jan; 29(1 Suppl 1):S1-24. PubMed ID: 9445124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S100A6 protein expression is different in Spitz nevi and melanomas.
    Ribé A; McNutt NS
    Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
    Boyd AS; Shakhtour B; Shyr Y
    J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations.
    Piris A; Mihm MC; Hoang MP
    Hum Pathol; 2015 Feb; 46(2):239-45. PubMed ID: 25479927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
    Googe PB; Flanigan KL; Miedema JR
    Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma?
    Skender-Kalnenas TM; English DR; Heenan PJ
    J Am Acad Dermatol; 1995 Dec; 33(6):1000-7. PubMed ID: 7490345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A subgroup of melanocytic nevi on the distal lower extremity (ankle) shares features of acral nevi, dysplastic nevi, and melanoma in situ: a potential misdiagnosis of melanoma in situ.
    Khalifeh I; Taraif S; Reed JA; Lazar AF; Diwan AH; Prieto VG
    Am J Surg Pathol; 2007 Jul; 31(7):1130-6. PubMed ID: 17592281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
    Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
    J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The intermediate filament peripherin is expressed in cutaneous melanocytic lesions.
    Prieto VG; McNutt NS; Lugo J; Reed JA
    J Cutan Pathol; 1997 Mar; 24(3):145-50. PubMed ID: 9085149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TSLC1 expression discriminates cutaneous melanomas from dysplastic nevi.
    You Y; Wang SH; Zhang JF; Zheng SY
    Melanoma Res; 2012 Dec; 22(6):430-5. PubMed ID: 23047161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.
    Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA
    Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of insulin-like growth factor-binding protein 2 in melanocytic lesions.
    Wang H; Shen SS; Wang H; Diwan AH; Zhang W; Fuller GN; Prieto VG
    J Cutan Pathol; 2003 Nov; 30(10):599-605. PubMed ID: 14744083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical expression of VEGF, HIF1-a, and PlGF in malignant melanomas and dysplastic nevi.
    Konstantina A; Lazaris AC; Ioannidis E; Liossi A; Aroni K
    Melanoma Res; 2011 Oct; 21(5):389-94. PubMed ID: 21876459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular analysis of melanoma precursor lesions.
    Wang Y; Rao U; Mascari R; Richards TJ; Panson AJ; Edington HD; Shipe-Spotloe JM; Donnelly SS; Kirkwood JM; Becker D
    Cell Growth Differ; 1996 Dec; 7(12):1733-40. PubMed ID: 8959342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.